365上市公司(英国)集团官方网站-Best Macau Store

XIE Yuehui (谢粤辉), aged 55, is the chairman, Chief Executive Officer and an executive Director. Mr. XIE has served as the director of Lifetech Shenzhen since October 2000 and was promoted to serve as the chairman of Lifetech Shenzhen since 2005. During the period from 2011 to 2023, Mr. XIE was appointed as a director of three overseas subsidiaries and 11 PRC subsidiaries of the Group. In 2024, Mr. XIE resigned from one PRC subsidiary of the Group as a director. Mr. XIE is primarily responsible for the Group's overall strategic planning and the management of the Group's business. Mr. XIE has about 34 years of experience in business management in the PRC, including over 22 years in the medical device industry. In June 2015, Mr. XIE was appointed as a representative of the Sixth Shenzhen Municipal People's Congress. From 1991 to 1993, Mr. XIE served as the project manager of Eastern Tantalum Group (东方钽业集团). From June 1993 to January 1994, Mr. XIE was the investment manager at a subsidiary of China Southern Securities (南方证券), and was responsible for project investment. From February 1994 to February 1996, Mr. XIE held the position of the deputy general manager at an investment branch of Bank of China, Jilin Province, and was responsible for managing futures investment projects. From February 1996 to December 1998, Mr. XIE served as the manager at the domestic trade department of Shenzhen Huihua Group (深圳市汇华集团) and was responsible for overall trade management. Since June 1998, Mr. XIE was a general manager at Shenzhen Huishibang Technology Company Limited (深圳市汇世邦科技有限公司) and was promoted to its chairman in 2000. During this period, Mr. XIE was responsible for overall business management. Mr. XIE graduated from Kunming Institute of Technology (昆明工学院) in July 1991 with a bachelor's degree in materials specialising in pressurised processing of metals (金属压力加工专业). He also obtained a master's degree in business administration from Tsinghua University in July 2006.

LIU Jianxiong (刘剑雄), aged 54, is the Executive Vice President, Chief Financial Officer, Company Secretary and an executive Director. He was appointed as a non-executive Director on 2 March 2015 and was subsequently re-designated as an executive Director with effect from 27 March 2015. On 13 July 2017, he was promoted to serve as Vice President. On 12 April 2019, he was further promoted to serve as Executive Vice President. Mr. LIU joined the Group in September 2010 and he has been appointed as a director of a number of the Company's subsidiaries, including LifeTech Scientific (Europe) B.V., LifeTech Scientific (Netherlands) B.V., Dongguan LifeTech-Quantum Medical Technology Co., Ltd., Lifetech Scientific America Corporation and LifeTech Scientific International Holding Limited successively since 2015. Mr. LIU was also appointed as the supervisor of Shenzhen LifeTech Innovation Medical Investment Co., Ltd. (深圳市英国正版365官方网站创新医疗投资有限公司) in 2020. Mr. LIU has about 32 years of experience in the accounting field. He started his career as an auditor at Kwan Wong Tan & Fong (currently Deloitte Touche Tohmatsu) in 1993, and was primarily responsible for carrying out audits and consultancy work. Mr. LIU then continued to work with a number of multinational companies. From 1997 to 2001, he was the accounting services manager of Yantian International Container Terminal Company Limited (盐田国际集装箱码头有限公司). From 2001 to 2003, Mr. LIU was the financial controller of Shenzhen Schlumberger Electronic System Solution Co., Ltd. (深圳斯伦具谢电子系统有限公司). From March 2007 to July 2007, Mr. LIU was the China financial controller of China Light & Power Group's renewable energy division. From December 2007 to February 2010, Mr. LIU was the corporate controller of AnyDATA Group in the Great China, and was responsible for financial management, accounts audit, tax planning, raising capital and preparation of financial accounts in accordance with accounting standards in PRC, U.S. and Hong Kong. He has been a member of the Association of Chartered Certified Accountants since 1997 and a registered tax agent since 1999. Mr. LIU graduated from Zhongshan University's faculty of physics with a major in modern physics technology in July 1990. He obtained a master's degree in business administration from University of Glamorgan in the United Kingdom in December 2004.

Ms. WU Liping, aged 45, holds a bachelor's degree and is currently pursuing an EMBA at the University of Hong Kong — Peking University. Ms. Wu has been deeply engaged in the field of vascular minimally invasive therapy for over 20 years. Since joining the Group in 2006, she has established the market systems and product portfolio for the aortic and peripheral vascular businesses of the Group. Ms. Wu is currently serving as the vice president of the Group, where she is responsible for the overall operation, management, strategy formulation and execution of the comprehensive pan-vascular business segment. She also holds directorships, legal representative roles, and senior management positions in several of the Group's subsidiaries and joint ventures.

During her tenure, Ms. Wu spearheaded the research and development, clinical registration, market access, and commercialisation strategies for multiple innovative medical devices. She has been instrumental in driving the transformation of the Group's aortic business from a single-product focus towards offering integrated pan-vascular solutions. Ms. Wu has achieved several breakthroughs in aortic endovascular treatment innovations and the commercialisation of domestically developed high-end medical devices. She pioneered the Group's strategic expansion into new pan-vascular sectors, propelling the sustained development and scalable growth of the peripheral vascular business. Concurrently, she accelerated the Group's collaboration and capability building in industry-academia-research initiatives, leading synergistic partnerships with numerous universities and clinical institutions. These efforts have substantially strengthened the Group's foundational capabilities in original product innovation, clinical demand translation, and cross-disciplinary collaboration.

Ms. Wu was awarded the First Prize of the 2024 Chinese Medical Science and Technology Award and the First Prize of the 2024 Military Science and Technology Progress Award. She holds several relevant invention patents and consecutively received the Shenzhen Industrial Development and Innovation Talent Award from 2019 to 2021. She also serves as a committee member of the vascular surgery branch of the Jiangsu Research Hospital Association and acts as an external postgraduate supervisor for the Textiles College of Donghua University.

Mr. FANG Yu, aged 47, holds a bachelor’s and master’s degree in Polymer Materials Science and Engineering from Tsinghua University. Mr. Fang has over 20 years of experience in the medical device industry. Mr. Fang currently serves as the vice president of the Group, where he is primarily responsible for the overall coordination and strategic execution of the structural heart diseases and electrophysiology business. Mr. Fang also serves as a chairman, director, supervisor, legal representative and senior management of various subsidiaries, associates and joint ventures of the Group. Since assuming his current position in the Group in 2016, he has led the structural heart department to achieve rapid sales growth, spearheaded the comprehensive market launch and promotion of the Group's Left Atrial Appendage Occluder, and driven improvements and optimisation of existing products while exploring new business areas and incubating new products. Mr. Fang possesses extensive project management expertise and innovation capability, holds several relevant invention patents, and consecutively received the Shenzhen Industrial Development and Innovation Talent Award from 2019 to 2021. Prior to joining the Group, he worked at Johnson & Johnson (Shanghai) Medical Devices Limited and St. Jude Medical (Shanghai) Co., Ltd.

Ms. FENG Xiaoling, aged 54, holds a MBA from the Shanghai University of Finance and Economics and has over 25 years of corporate management experience, with notable achievements in international business expansion. Ms. Feng currently serves as the vice president of the Group, with responsibility for the Group's international market development, cross-border business cooperation, and global resource integration. Ms. Feng also serves as a director, legal representative and senior management of various subsidiaries, associates and joint ventures of the Group. Since joining the Group in 2017, she has successfully led the establishment of an in-depth market network in over 100 countries and regions worldwide, driving the international commercialisation of multiple innovative medical device products. Under her leadership, the Group's international layout has become increasingly robust, with global subsidiaries and offices developing synergistically and the sales network continuously expanding, significantly enhancing the Group's brand influence and competitiveness in the international market. Prior to joining the Group, Ms. Feng held senior executive positions at several multinational corporations.

JIANG Feng (姜峰), aged 62, was appointed as a non-executive Director on 1 April 2014. Mr. JIANG is currently vice president of China Association for Medical Devices Industry, chairman of China Strategic Alliance of Medical Devices Innovation, deputy director of Biomedical Engineering Education Steering Committee of the Ministry of Education (教育部生物医学工程专业教育指导委员会) and chairman of TC94 sub-committee of National Standards Technical Committee (国家标准技术委员会). Mr. JIANG had been working as a clinician for 12 years before he left the hospital in 1997 to establish his own business. For his outstanding achievements, Mr. JIANG was considered to be special talent by SASAC and was chosen to be a leader of national large medicine and device companies for a long term, including as chairman and general manager of China National Pharmaceutical Group Corporation North West Company and China National Medical Equipment Co., Ltd.. During that period, Mr. JIANG was in charge of or participated in restructuring, mergers and acquisitions and transformations for the listing of nearly 40 relevant companies. Mr. JIANG served as a general manager of China National Medical Equipment Co., Ltd. for 9 years, during which he accomplished the substantial transformation of the enterprise from an exhibition business to the production and operation of medical devices by establishing China's first Sino-foreign joint venture medical device distribution company and making it the largest domestic medical device distributor within 5 years. Mr. JIANG had been president and standing vice president of China Association for Medical Devices Industry for 22 years, during which he visited and evaluated over a thousand of member enterprises. For around 15 years as a chairman of China Strategic Alliance of Medical Devices Innovation, he has been assisting the science and technology department and local science and technology bureaus in assessing subjects of hundreds of medical device projects and conducting subsequent management. Benefiting from his extensive work experience in the industry, Mr. JIANG is expert at the operation and management of medical companies and understands development trends of the industry, particularly in industrial innovation and international marketing. Since 8 November 2016, Mr. JIANG was appointed as an independent non-executive director of Hangzhou Kangji Medical Instrument Co., Ltd. for a term of three years. Since January 2022, Mr. JIANG was appointed as an independent director of Eyebright Medical Technology (Beijing) Inc. for a term of three years. Since December 2022, Mr. JIANG was appointed as an independent director of Dynamiker Biotechnology (Tianjin) Co., Ltd. and resigned in June 2023. Since April 2023, Mr. JIANG has been appointed as an independent director of SWS Hemodialysis Care Co., Ltd.. Since September 2023, Mr. JIANG has been appointed as an independent director of Inkon Life Technology Co., Ltd.. Mr. JIANG graduated from the Fourth Military Medical University with a bachelor's degree in Medicine in 1985 and obtained his doctoral degree in clinical surgery in 1995 from the Fourth Military Medical University. He obtained an EMBA degree from Tsinghua University in 2007.

WANG Wansong (王皖松), aged 55, was appointed as an independent non-executive Director on 29 January 2016. Mr. WANG is currently the director of Shenzhen YUTO Foundation (深圳市裕同公益基金会), the partner of Shenzhen Songhe International Capital Fund and has been engaged in high-tech industry development planning and policy research for a long time, he has extensive experience in technological innovation, achievements transformation for the bio-pharmaceutical industry and medical device industry. From 1997 to 2014, Mr. WANG worked at Development and Reform sectors of the Shenzhen Government. From 2014 to 2018, Mr. WANG was appointed as a senior researcher at the State High-Tech Industrial Innovation Center in Shenzhen (深圳市国家高技术产业创新中心). Mr. WANG holds a bachelor's degree in biology from Peking University.

ZHOU Luming (周路明), aged 66, was appointed as an independent non-executive Director with effect from 1 April 2014. Mr. ZHOU is currently the president of the Shenzhen CRI Innovation Center (深圳市源创力离岸创新中心) and the chairman of Shenzhen CRI Qingyuan Investment Management Co., Ltd. (深圳市源创力清源投资管理有限公司). He was a teacher in South-Central Minzu University from July 1984 to May 1992. During that period, he published a professional work titled Systems Science (系统科学) together with a number of academic papers. From May 1992 to September 2001, he worked in the Shenzhen Technology Bureau (深圳市科技局) as the head of the compliance division, director of general office and head of the planning division, taking charge of the establishment of a series of major legislations and research on decision-making work. Mr. ZHOU acted as deputy dean of the Research Institute of Tsinghua University in Shenzhen from September 2001 to May 2004. He was deputy director of the Shenzhen Technology Bureau from May 2004 to May 2008. During the period from 2005 to 2008, Mr. ZHOU presided over series of study on innovative cities. From 2008 to March 2014, when he served as chairman of the Shenzhen Science and Technology Association, he established a great number of private-funded research institutes of international advanced level, which involved metamaterial, new energy and precise manufacturing. His experience in directing the restructuring of the Shenzhen Science and Technology Association was highly appreciated by major leaders of the China Association of Science and Technology and was promoted within the system of the associations of science and technology. Mr. ZHOU graduated from the Faculty of Physics of Central China Normal University in 1984, and obtained his EMBA degree after graduating from Tsinghua University in 2005.

Ms. CHEN Dongxia, aged 49, is a senior professional in financial investment and asset management with over 20 years of experience in cross-border capital operations and merger and acquisition investments. She holds dual bachelor’s degrees in Accounting and International Business from Jinan University in China, as well as a master’s degree in Accounting and Finance from the University of Sydney in Australia. She also holds professional qualifications including CFA, FCPA, and ESG Investing, and is licensed by the Hong Kong Securities and Futures Commission as a Responsible Officer (RO) for Type 4 (Advising on Securities) and Type 9 (Asset Management) regulated activities. 

Ms. Chen is currently the Council Member of the Hong Kong China Financial Association, she served as Deputy General Manager of China Resources Healthcare Group Limited, Deputy General Manager of the Finance Department of China Resources Group, and General Manager of Finance at CR Capital. She has extensive experience in cross-border investments, mergers and acquisitions, and private equity funds, and has led multiple major capital transactions and the establishment and fundraising of various private equity funds. 

Ms. Chen is fluent in both Chinese and English, well-versed in diverse capital market environments, and brings both an international perspective and strong localized execution capabilities.